{"id":296216,"date":"2026-07-10T00:00:00","date_gmt":"2026-07-10T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0033-2024-biopharma-axial-spondyloarthritis-current-treatment-treatment-algorithms-claims-data\/"},"modified":"2026-07-25T23:12:29","modified_gmt":"2026-07-25T23:12:29","slug":"algoim0033-2026-biopharma-axial-spondyloarthritis-current-treatment-treatment-algorithms-claims-data-analysis","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0033-2026-biopharma-axial-spondyloarthritis-current-treatment-treatment-algorithms-claims-data-analysis\/","title":{"rendered":"Axial Spondyloarthritis &#8211; Current Treatment &#8211; Treatment Algorithms: Claims Data Analysis &#8211; Ankylosing Spondylitis (US)"},"content":{"rendered":"<p>Ankylosing spondylitis (<abbr title=\"ankylosing spondylitis\">AS<\/abbr>) is a chronic inflammatory disease that primarily affects the sacroiliac joints and the axial skeleton, leading to persistent back pain and stiffness. The main treatment goals include alleviating the signs and symptoms, improving physical function, preventing disability, and slowing or preventing structural damage. <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-alpha inhibitors such as AbbVie\u2019s Humira, Amgen\u2019s Enbrel, Johnson &#038; Johnson Innovative Medicine\u2019s Remicade and Simponi \/ Simponi Aria, <abbr title=\"Union Chimique Belge\">UCB<\/abbr>\u2019s Cimzia, can effectively reduce disease activity in <abbr title=\"ankylosing spondylitis\">AS<\/abbr>, particularly in patients who require potent therapies beyond first-line <abbr title=\"nonsteroidal anti-inflammatory drug\">NSAID<\/abbr>s. The <abbr title=\"interleukin\">IL<\/abbr>-17 inhibitors, Novartis\u2019s Cosentyx, Eli Lilly\u2019s Taltz, and <abbr title=\"Union Chimique Belge\">UCB<\/abbr>\u2019s Bimzelx, offer an alternative <abbr title=\"mechanism of action\">MOA<\/abbr> to <abbr title=\"tumor necrosis factor\">TNF<\/abbr> inhibition. The novel <abbr title=\"Janus kinase\">JAK<\/abbr> inhibitor class comprises Pfizer\u2019s Xeljanz and AbbVie\u2019s Rinvoq, which are the only nonbiological targeted therapies for <abbr title=\"ankylosing spondylitis\">AS<\/abbr>.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed <abbr title=\"ankylosing spondylitis\">AS<\/abbr> patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed <abbr title=\"ankylosing spondylitis\">AS<\/abbr> patients?<\/li>\n<li>How has Bimzelx been integrated into the treatment algorithm, and what is its source of business?<\/li>\n<li>What percentage of <abbr title=\"ankylosing spondylitis\">AS<\/abbr> patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li>What percentage of <abbr title=\"ankylosing spondylitis\">AS<\/abbr> patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States<\/p>\n<p><strong>Real-world data: <\/strong>U.S. pharmacy and medical claims data<\/p>\n<p><strong>Key drugs covered<\/strong>: Humira, Enbrel, Cimzia, Remicade, Simponi, Cosentyx, Taltz, Xeljanz, Rinvoq, <abbr title=\"nonsteroidal anti-inflammatory drug\">NSAID<\/abbr>s<\/p>\n<p><strong>Key analyses<\/strong>: Brand \/ therapy usage across longitudinal patient sample, newly diagnosed patient analysis, treatment initiation and progression, line of therapy analysis, combination therapy analysis, source of business for recently treated patients, persistency and compliance analysis, product-level patient flow charts<\/p>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<div>\n<p>Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:<\/p>\n<\/div>\n<div>\n<ul class=\"BulletListStyle1 SCXW73915144 BCX0 round-bullets\">\n<li>Understand patient flow between lines of therapy.<\/li>\n<li>Evaluate your brand share against competitors.<\/li>\n<li>Accurately assess your source of business.<\/li>\n<li>Quantify opportunities at different stages of the treatment algorithm.<\/li>\n<\/ul>\n<p><strong>Product enhancement<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis leverages Clarivate\u2019s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.<\/p>\n<\/div>\n","protected":false},"template":"","class_list":["post-296216","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-ankylosing-spondylitis","biopharma-therapy-areas-axial-spondyloarthritis","biopharma-therapy-areas-rheumatology","biopharma-product-current-treatment","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296216","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=296216"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}